STAT April 7, 2024
Matthew Herper

A new analysis published Sunday challenges the clinical trial endpoint the cancer screening firm Grail is using to evaluate its blood test aimed at simultaneously detecting multiple types of tumors early.

Grail’s test, called Galleri, is available in the U.S. but not yet approved by the Food and Drug Administration or reimbursed by Medicare except as part of a particular clinical trial. According to reports...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma / Biotech, Trends
Pepper Bio spices up pipeline with $135M deal for G1 Therapeutics' CDK4/6 inhibitor
BIO survey to elucidate US biopharma's reliance on Chinese CDMOs amid decoupling threats
Lilly uses Mounjaro millions to hunt for biotech partners
FTC cracks down on drug patents
Methods To Alter Cellular Gene Expression

Share This Article